Biotech News

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Lenz Therapeutics Inc (LENZ)Lenz Therapeutics Inc2026-05-26 12:00 ESTCompany update

LENZ (LENZ) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lenz.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

LENZLenz Therapeutics Inc2026-02-23 13:00 EST

LENZ Therapeutics to Present at Upcoming Investor Conferences

LENZLenz Therapeutics Inc2026-05-04 12:00 EST

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

OCSOculis2026-04-07 08:00 EST

Oculis to Participate in Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2026-02-26 21:30 EST

Tarsus to Participate in Upcoming Investor Conferences

VRDNViridian Therapeutics2021-11-03 20:05 EST

Viridian Therapeutics to Present at Upcoming Investor Conferences

OCULOcular Therapeutix2026-07-01 11:00 EST

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

OCULOcular Therapeutix2026-04-27 11:00 EST

Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

SGHTSight Sciences2026-04-29 20:05 EST

Sight Sciences to Present at Two Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2025-11-24 21:30 EST

Tarsus to Participate in Upcoming Investor Conference

VRDNViridian Therapeutics2022-04-06 12:00 EST

Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

View all latest news

Lenz Therapeutics Inc

LENZ Therapeutics is an ophthalmology company focused on presbyopia and eye-care treatments. Its story is centered on bringing a differentiated eye-health product to a large but competitive market.

Recent company news

LENZLenz Therapeutics Inc2026-07-06 12:15 EST

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

LENZLenz Therapeutics Inc2026-06-24 12:30 EST

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

LENZLenz Therapeutics Inc2026-06-07 23:30 EST

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

LENZLenz Therapeutics Inc2026-05-26 12:00 EST

LENZ Therapeutics to Participate in Upcoming Investor Conferences

LENZLenz Therapeutics Inc2026-05-11 20:05 EST

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Stock data

Close: 5.70 USD
Market cap: 223.56M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States